Costus: Anti-Inflammatory and Analgesic Evidence

Ayurvedic tradition uses crepe ginger rhizome for fever, rheumatism and painful conditions, and the modern rodent literature testing that use is more substantial than most single-herb inflammation literatures on this site — five independent groups, six different pain and inflammation models, a full cytokine panel, and named compounds behind the effect. It is also a literature with a real, checkable design problem sitting in plain sight, and one paper that needs unusually careful handling so it does not accidentally resurrect the hormone myth this site has already put to rest from a different angle.

Table of Contents

1. The Traditional Claim
2. Rhizome or Aerial Parts? A Part-Substitution Problem
3. Oedema, Granuloma and Arthritis Models
4. Pain and Fever Models
5. The Cytokine-Level Mechanism
6. The Named Compounds Behind the Effect
7. A 2025 Psoriasis Model
8. The Rheumatoid-Arthritis Fertility Study, Read Carefully
9. A Computational-Only Study, and Why That Tier Matters
10. What a Real Trial Would Measure
11. Key Research Papers
12. Connections

The Traditional Claim

Crepe ginger rhizome appears across Ayurvedic and regional Southeast Asian practice for fever, rheumatism, inflammation, cough, asthma and painful skin conditions — the general profile of a bitter, cooling drug used against heat and swelling. Duraipandiyan and colleagues, introducing their own antimicrobial study of the plant, summarise the traditional indication list plainly: rhizomes used to treat “pneumonia, rheumatism, dropsy, urinary diseases, jaundice, skin diseases,” with leaves used separately for mental disorders. This page covers what the modern pharmacology says about the inflammation and pain portion of that list specifically.

Back to Table of Contents

Rhizome or Aerial Parts? A Part-Substitution Problem

Before the results, a design issue that a casual read of this literature will miss entirely, because the species name and the word “extract” match in every paper.

The rhizome is what tradition uses and what commerce sells. Every traditional-use description on the main Costus page, and every antidiabetic and antimicrobial study covered on this site’s other three Benefit pages, works with the rhizome. But two of the most methodologically thorough anti-inflammatory studies in this literature — Srivastava and colleagues’ 2012 anti-arthritic study and their 2013 companion paper on anti-inflammatory, analgesic and antipyretic activity — both explicitly used methanolic extract of the aerial parts, not the rhizome.

This matters for the same reason a root result should not be read onto a leaf preparation anywhere else on this site: different plant organs make different concentrations of different compounds, and nothing in either Srivastava paper establishes that the aerial-part chemistry driving their positive results is present in the same proportions in the rhizome that tradition and every commercial product actually use. It does not mean the aerial-parts results are wrong. It means two of this page’s strongest anti-arthritic and anti-inflammatory findings technically support a different part of the plant than the one being sold, and that distinction is worth holding onto rather than blurring, exactly as this site’s doctrine requires for any part substitution.

The rhizome-specific literature is not thin, however — Binny, Al-Attas, Bhattacharya, Selim and Gheraibia’s studies below all work directly with rhizome material, so the traditional target organ does have its own independent support. The point is simply to keep the two bodies of evidence separated rather than pooled.

Back to Table of Contents

Oedema, Granuloma and Arthritis Models

Three separate, standard rodent inflammation models have been run against this plant, by two independent groups, with consistent positive results.

• Carrageenan-induced paw oedema — the standard acute-inflammation screening model, where a carrageenan injection into a rat’s hind paw produces measurable swelling within hours. Binny, Kumar and Dennis (2010) found significant anti-inflammatory effect against carrageenan oedema using ethanolic rhizome extract at 800 mg/kg. Srivastava and colleagues (2013) found a dose-dependent effect using methanolic aerial-part extract at 400 and 800 mg/kg, with 19.4% and 40.1% reduction respectively at five hours post-dose.
• Cotton-pellet-induced granuloma — a model of the chronic, proliferative phase of inflammation rather than the acute phase, where a sterile cotton pellet implanted under the skin triggers granulation tissue formation over several days. Binny and colleagues found significant effect against this model too, at both 400 and 800 mg/kg of rhizome extract — a genuinely useful second data point, because acute and chronic inflammation are pharmacologically distinct processes and an agent that works on one does not automatically work on the other.
• Freund’s-adjuvant-induced arthritis — a model of chronic, immune-mediated joint inflammation closer to rheumatoid arthritis than to a simple acute injury. Srivastava and colleagues (2012), using methanolic aerial-part extract, reported 75.5% and 68.3% protection against paw-oedema increase at 400 and 800 mg/kg respectively — a substantial effect size, in the model most relevant to a chronic arthritic condition, though note again this is the aerial-parts study.

Back to Table of Contents

Pain and Fever Models

Beyond swelling, three studies address pain and fever directly, using standard, validated rodent assays.

• Acetic-acid-induced writhing — a visceral-pain model where an irritant injection causes a stereotyped abdominal-contraction (“writhing”) response, and an effective analgesic reduces the writhe count. Bhattacharya and Nagaich (2010) tested both aqueous and ethanolic rhizome extracts, finding the aqueous extract significantly inhibited writhing at 75 and 150 mg/kg, and the ethanolic extract at 150 mg/kg. Srivastava and colleagues (2013) found a similar effect with aerial-part extract, inhibiting writhing by 14.2% and 31.9% at their two doses.
• Hot-plate / tail-flick, a thermal-pain model of central analgesia — this is the more informative of the two pain assays, because writhing can be produced by a peripheral, purely local anti-inflammatory effect, while a hot-plate or tail-flick result implies action reaching the central nervous system. Bhattacharya’s tail-flick data found only the ethanolic rhizome extract showed significant central analgesic action; the aqueous extract was entirely ineffective in this specific assay, despite working in the writhing test. Srivastava’s hot-plate data with aerial-part extract found an increased latency period at both doses (16.6 and 14.1 seconds versus control).
• Brewer’s-yeast-induced pyrexia — a standard fever model. Binny’s rhizome-extract study found only a minimal antipyretic effect, and only at the higher 800 mg/kg dose. Srivastava’s aerial-part study found a more convincing reduction in rectal temperature at both doses.

Read together, the solvent-dependence in Bhattacharya’s tail-flick result is worth flagging on its own: it means whatever compound produces central analgesia is more efficiently extracted by ethanol than by water, which has the same practical implication as this site’s recurring solvent-substitution caution elsewhere — a traditional water decoction and an ethanolic tincture are not guaranteed to deliver the same effect, even from the identical rhizome.

Back to Table of Contents

The Cytokine-Level Mechanism

The most methodologically detailed study in this set moves past “the extract reduced swelling” to a named molecular mechanism. Al-Attas and colleagues (2015) isolated eight individual compounds from Costus speciosus rhizome by repeated chromatography, then measured each compound’s effect on six separate inflammatory markers — IL-6, IL-1β, TNF-α, COX-2, lipoxygenase-5, and PGE2 — by enzyme-linked immunosorbent assay. Four of the eight compounds (a new eudesmane acid the authors named specioic acid, plus stigmasterol, arbusculin A and one further compound) showed the strongest activity, reducing all six markers to levels statistically indistinguishable from untreated control cells at higher test concentrations. Two compounds (arbusculin A and santamarine) showed no significant effect at low concentration but became active at 100 µM.

Separately, Selim and Al Jaouni’s 2016 diosgenin study, covered in more depth on the diosgenin page, found that diosgenin isolated from this plant suppressed TNF-α release from LPS-stimulated macrophages to a degree comparable with methotrexate, a real disease-modifying anti-rheumatic drug — a genuinely striking comparator, though it remains a cell-culture result, not a treatment claim.

This is a coherent, hypothesis-consistent mechanism: named compounds, named cytokine and enzyme targets, a plausible route from “isolated compound suppresses TNF-α and COX-2 in a dish” to “crude extract reduces paw swelling in a rat.” It remains, at every step, cell-culture and animal-model evidence with no human confirmation.

Back to Table of Contents

The Named Compounds Behind the Effect

Worth listing precisely, because this is unusually well-characterised chemistry for a plant on this site. The rhizome’s anti-inflammatory activity is attributed, across these studies, to a family of sesquiterpene lactones and related terpenoids: costunolide, dehydrocostus lactone (also called mokko lactone in its dehydrodihydro form), eremanthin, arbusculin A, santamarine (douglanin), reynosin, and the newly described specioic acid, alongside the steroid stigmasterol and diosgenin itself. This is the same compound family covered in chemical detail on the diosgenin page, including the reason it is worth checking for contact-allergy potential as a class. Here, the same molecules are doing anti-inflammatory rather than anticancer work — a reminder that a single compound family in this plant is pulling weight across several of this site’s Benefit pages simultaneously, which is a sign of a real, concentrated, well-studied chemistry rather than a diffuse “contains antioxidants” story.

Back to Table of Contents

A 2025 Psoriasis Model

A 2025 Indian study by Vyas and colleagues, already noted on the main Costus page, tested Costus speciosus extract as an immunomodulator in an imiquimod-induced psoriasis model in BALB/c mice, reporting effects attributed to the NF-κB pathway — the same transcription factor Al-Attas’s isolated compounds and Selim’s diosgenin both act on. Imiquimod-model psoriasis studies are extremely common across the plant-extract literature generally, and an NF-κB-mediated result is the expected finding rather than a distinctive one; it is included here for completeness and because it fits the same cytokine mechanism as the rest of this page, not because it is unusually strong evidence on its own.

Back to Table of Contents

The Rheumatoid-Arthritis Fertility Study, Read Carefully

One 2022 paper needs more careful handling than the others, because a loose summary of it would recreate, from a new angle, exactly the hormone-precursor confusion the diosgenin page and the main Costus page both work to clear up.

What Kamel and colleagues actually did. Male Wistar rats were given Freund’s-adjuvant-induced rheumatoid arthritis, a model of chronic autoimmune inflammation. Untreated, the arthritic rats showed reduced sex-organ weight, reduced sperm count, testicular degeneration, reduced androgen-receptor expression, and increased TNF-α and BAX protein — that is, the systemic inflammation of the arthritis model damaged testicular tissue and suppressed the receptors that respond to testosterone. Rats given Costus extract (200 or 400 mg/kg) alongside the arthritis induction showed improvement across all of these measures compared to untreated arthritic rats.

What this shows: an anti-inflammatory effect — consistent with every other finding on this page — that appears to protect testicular tissue and preserve existing androgen-receptor expression from inflammation-driven damage. That is a real and interesting finding within the anti-inflammatory literature.

What this does not show, and must not be allowed to imply: nothing here indicates Costus extract directly stimulates testosterone production, acts as a hormone precursor, or does anything resembling what diosgenin marketing claims. The proposed mechanism is protective and anti-inflammatory — shielding existing receptors and tissue from an inflammatory insult that would otherwise suppress them — not steroidogenic. Reading “androgen receptors were preserved” as “this herb boosts hormones” would be a new instance of the exact error the diosgenin page spends an entire page refuting from the chemistry-and-clinical-trial angle. This page refutes it from the mechanism angle instead: protecting a receptor from inflammatory damage is not the same event as synthesising the hormone that binds it, and this study demonstrates only the former.

Back to Table of Contents

A Computational-Only Study, and Why That Tier Matters

One more 2025 paper belongs on this page, filed at its correct evidentiary weight. Raj and colleagues screened eighteen phytocompounds identified by GC-MS from Costus speciosus rhizome against the TLR-4/AP-1 inflammatory signalling pathway — entirely by molecular docking and molecular dynamics simulation. One compound (a substituted benzenepropanoic acid methyl ester) showed the strongest predicted binding affinity and favourable predicted drug-like properties.

This is worth including for completeness and worth being precise about its tier. Molecular docking predicts whether a compound’s three-dimensional shape is compatible with binding a target protein’s active site, computed entirely on a computer, with no cells, no animals, and no laboratory bench work of any kind in this particular study. It is a genuinely useful tool for generating hypotheses and prioritising which compounds to test next — but it is a weaker form of evidence than any cell-culture or animal result on this page, several steps removed from Al-Attas’s actual ELISA-measured cytokine reductions. A docking score is not a demonstrated biological effect. This finding belongs in the record as a candidate for future wet-lab testing, not as confirmation of anything.

Back to Table of Contents

What a Real Trial Would Measure

A common defence of a traditional anti-inflammatory herb is that inflammation is too vague and subjective to trial properly. That defence does not hold up here. Rheumatology and pain medicine have decades of validated, standardised outcome measures built for exactly this purpose, and none of them has ever been pointed at crepe ginger. A competent human trial — for the arthritic, painful or febrile-illness indications this plant is traditionally used for — would report:

1. Inflammatory blood markers — C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), the two cheapest, most widely available objective measures of systemic inflammation, neither of which any study on this page has measured in a human subject.
2. A validated composite disease-activity score for whichever condition is being tested — DAS28 for rheumatoid arthritis, WOMAC for osteoarthritis — rather than an investigator’s general impression.
3. A validated pain scale, such as a visual analogue scale (VAS) or numerical rating scale, recorded by the patient rather than inferred from an animal’s withdrawal latency.
4. Specific cytokine panels — IL-6, IL-1β, TNF-α — drawing directly on the exact markers Al-Attas’s and Selim’s cell-culture work already used, to see whether a laboratory mechanism actually moves in a person taking the whole plant by mouth.
5. A placebo or active comparator arm, dosed and blinded, since fever and joint pain both fluctuate substantially on their own and both respond strongly to expectation.
6. A stated, sourced preparation — rhizome or aerial part, and by which solvent — given the part-substitution and solvent-dependence issues already documented on this page.

Every item on that list is routine, inexpensive by clinical-trial standards, and in continuous use for testing other anti-inflammatory agents. None has been applied to this plant. That is a statement about research priorities and funding, not about whether the question is answerable — and naming the missing measurements precisely is a stronger argument than any general hedge about traditional herbs being hard to study.

Back to Table of Contents

Key Research Papers

Every citation below was checked against the live PubMed record before being written onto this page, using a title/abstract-scoped, species-locked search to confirm the paper concerns this plant specifically.

1. Binny K, Kumar SG, Dennis T. Anti-inflammatory and antipyretic properties of the rhizome of Costus speciosus (Koen.) Sm. Journal of Basic and Clinical Pharmacy, 2010. — PubMed search
2. Bhattacharya S, Nagaich U. Assessment of anti-nociceptive efficacy of Costus speciosus rhizome in Swiss albino mice. Journal of Advanced Pharmaceutical Technology & Research, 2010. — PubMed search
3. Srivastava S, Singh P, Jha KK, Mishra G, Srivastava S, Khosa RL. Evaluation of anti-arthritic potential of the methanolic extract of the aerial parts of Costus speciosus. Journal of Ayurveda and Integrative Medicine, 2012. Aerial parts, not rhizome. — PubMed search
4. Srivastava S, Singh P, Jha KK, Mishra G, Srivastava S, Khosa RL. Antiinflammatory, Analgesic and Antipyretic Activities of Aerial Parts of Costus speciosus Koen. Indian Journal of Pharmaceutical Sciences, 2013. Aerial parts, not rhizome. — PubMed search
5. Al-Attas AA, El-Shaer NS, Mohamed GA, Ibrahim SR, Esmat A. Anti-inflammatory sesquiterpenes from Costus speciosus rhizomes. Journal of Ethnopharmacology, 2015. Eight isolated compounds against a six-marker cytokine panel. — PubMed search
6. Selim S, Al Jaouni S. Anti-inflammatory, antioxidant and antiangiogenic activities of diosgenin isolated from traditional medicinal plant, Costus speciosus (Koen ex.Retz.) Sm. Natural Product Research, 2016. TNF-α suppression comparable to methotrexate. — PubMed search
7. Vyas A, et al. Costus speciosus extract: a natural immunomodulator for treatment of psoriasis in BALB/c mice by NF-κB pathway. Journal of Immunoassay and Immunochemistry, 2025. — PubMed search
8. Gheraibia S, et al. Costus speciosus extract protects against the oxidative damage of zearalenone via modulation of inflammatory cytokines, Nrf2 and iNOS gene expression in rats. Toxicon, 2022. — PubMed search
9. Kamel S, Tag HM, Ebeid H, Khaled HE, Almallah AA, El-Naggar MS. Adverse effect of rheumatoid arthritis on male Wistar rat’s fertility: protective role of Costus extract. Environmental Science and Pollution Research, 2022. Read with the anti-inflammatory, not hormonal, mechanism caveat above. — PubMed search
10. Raj A, et al. Anti-inflammatory Potential of Costus speciosus rhizome Bioactive Phytochemicals: A Combined GC-MS and Computational Approach Targeting TLR-4 Signaling. Current Computer-Aided Drug Design, 2025. Molecular docking only; no wet-lab confirmation in this study. — PubMed search
11. Methotrexate mechanism and TNF-α suppression in rheumatoid arthritis — the drug-class comparator behind Selim’s diosgenin result. — PubMed search

Back to Table of Contents

Connections

• All Herbs
• Costus Benefits Hub
• Blood Sugar: The Real Human Evidence
• Diosgenin, Costunolide and the Industrial Chemistry — the same named compounds, and the allergy question.
• Antimicrobial and Antiviral Evidence
• Costus (Cheilocostus speciosus) — the main page.
• Rheumatoid Arthritis — the model condition behind the Freund’s-adjuvant and fertility studies.
• Osteoarthritis
• Psoriasis — the 2025 mouse model.
• Male Infertility — the outcome measured in the rheumatoid-arthritis fertility study.
• Turmeric — the site’s best-evidenced anti-inflammatory herb, for comparison of evidence quality.

Back to Table of Contents